NASDAQ:SYNH - Syneos Health Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $42.45 +0.69 (+1.65 %) (As of 05/24/2019 04:00 PM ET)Previous Close$42.45Today's Range$41.95 - $42.7852-Week Range$36.26 - $56.34Volume381,051 shsAverage Volume731,156 shsMarket Capitalization$4.40 billionP/E Ratio16.20Dividend YieldN/ABeta1.36 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Syneos Health, Inc. operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process. The Commercial Solutions segment provides commercialization services, including medication adherence, communications, and consulting services. Its customers include small, mid-sized, and large companies in the pharmaceutical, biotechnology, and medical device industries. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina. Receive SYNH News and Ratings via Email Sign-up to receive the latest news and ratings for SYNH and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Commercial physical research Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SYNH Previous Symbol CUSIPN/A CIK1610950 Webhttp://www.syneoshealth.com/ Phone919-876-9300Debt Debt-to-Equity Ratio1.07 Current Ratio1.02 Quick Ratio1.02Price-To-Earnings Trailing P/E Ratio16.20 Forward P/E Ratio15.90 P/E Growth1.51 Sales & Book Value Annual Sales$4.39 billion Price / Sales1.00 Cash Flow$5.3396 per share Price / Cash Flow7.95 Book Value$27.36 per share Price / Book1.55Profitability EPS (Most Recent Fiscal Year)$2.62 Net Income$24.28 million Net Margins0.42% Return on Equity9.55% Return on Assets3.73%Miscellaneous Employees24,000 Outstanding Shares103,755,000Market Cap$4.40 billion Next Earnings Date8/1/2019 (Estimated) OptionableOptionable Syneos Health (NASDAQ:SYNH) Frequently Asked Questions What is Syneos Health's stock symbol? Syneos Health trades on the NASDAQ under the ticker symbol "SYNH." How were Syneos Health's earnings last quarter? Syneos Health Inc (NASDAQ:SYNH) released its quarterly earnings data on Thursday, May, 9th. The company reported $0.59 EPS for the quarter, beating analysts' consensus estimates of $0.51 by $0.08. The company earned $1.12 billion during the quarter, compared to analyst estimates of $1.09 billion. Syneos Health had a net margin of 0.42% and a return on equity of 9.55%. Syneos Health's revenue was up 5.8% compared to the same quarter last year. During the same period last year, the business earned $0.55 earnings per share. View Syneos Health's Earnings History. When is Syneos Health's next earnings date? Syneos Health is scheduled to release their next quarterly earnings announcement on Thursday, August 1st 2019. View Earnings Estimates for Syneos Health. What guidance has Syneos Health issued on next quarter's earnings? Syneos Health issued an update on its FY19 earnings guidance on Thursday, May, 9th. The company provided earnings per share guidance of $3.03-3.23 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.12. The company issued revenue guidance of $4.62-4.73 billion, compared to the consensus revenue estimate of $4.58 billion.Syneos Health also updated its FY 2019 guidance to $3.03-3.23 EPS. What price target have analysts set for SYNH? 10 analysts have issued 12-month price objectives for Syneos Health's stock. Their predictions range from $48.00 to $60.00. On average, they anticipate Syneos Health's stock price to reach $54.6250 in the next twelve months. This suggests a possible upside of 28.7% from the stock's current price. View Analyst Price Targets for Syneos Health. What is the consensus analysts' recommendation for Syneos Health? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syneos Health in the last year. There are currently 4 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Syneos Health. Has Syneos Health been receiving favorable news coverage? Media coverage about SYNH stock has been trending positive this week, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Syneos Health earned a coverage optimism score of 2.3 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future. Who are some of Syneos Health's key competitors? Some companies that are related to Syneos Health include Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), Charles River Laboratories Intl. (CRL), Exelixis (EXEL), PRA Health Sciences (PRAH), BTG (BTGGF), Medpace (MEDP), Intrexon (XON), Geovax Labs (GOVX), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX), STARPHARMA HOLD/S (SPHRY), Pieris Pharmaceuticals (PIRS) and Anavex Life Sciences (AVXL). What other stocks do shareholders of Syneos Health own? Based on aggregate information from My MarketBeat watchlists, some companies that other Syneos Health investors own include Icon (ICLR), NVIDIA (NVDA), Netflix (NFLX), Square (SQ), AT&T (T), UnitedHealth Group (UNH), Paypal (PYPL), Skyworks Solutions (SWKS), Alibaba Group (BABA) and Caterpillar (CAT). Who are Syneos Health's key executives? Syneos Health's management team includes the folowing people: Mr. Alistair Macdonald, CEO & Director (Age 49)Mr. Jason M. Meggs, Chief Financial Officer (Age 43)Mr. Jonathan Olefson, Gen. Counsel & Corp. Sec. (Age 43)Mr. Michael Adam Bell, Consultant (Age 63)Mr. Robert Parks, Exec. VP & Chief Accounting Officer Who are Syneos Health's major shareholders? Syneos Health's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.06%), Wellington Management Group LLP (3.75%), Clearbridge Investments LLC (3.16%), ArrowMark Colorado Holdings LLC (2.26%), Viking Global Investors LP (2.14%) and Goldman Sachs Group Inc. (1.87%). Company insiders that own Syneos Health stock include Alistair Macdonald, Christopher L Gaenzle, Gregory S Rush, H Lee Equity Fund Vi Thomas, Jason M Meggs and Jonathan Olefson. View Institutional Ownership Trends for Syneos Health. Which institutional investors are selling Syneos Health stock? SYNH stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, ArrowMark Colorado Holdings LLC, Goldman Sachs Group Inc., Wells Fargo & Company MN, Dimensional Fund Advisors LP, Marshall Wace North America L.P., Marshall Wace LLP and Retirement Systems of Alabama. Company insiders that have sold Syneos Health company stock in the last year include Alistair Macdonald and H Lee Equity Fund Vi Thomas. View Insider Buying and Selling for Syneos Health. Which institutional investors are buying Syneos Health stock? SYNH stock was purchased by a variety of institutional investors in the last quarter, including Viking Global Investors LP, Rubric Capital Management LP, Rothschild & Co. Asset Management US Inc., Voya Investment Management LLC, Boston Partners, Pictet Asset Management Ltd., ClariVest Asset Management LLC and Geode Capital Management LLC. Company insiders that have bought Syneos Health stock in the last two years include Jason M Meggs and Jonathan Olefson. View Insider Buying and Selling for Syneos Health. How do I buy shares of Syneos Health? Shares of SYNH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Syneos Health's stock price today? One share of SYNH stock can currently be purchased for approximately $42.45. How big of a company is Syneos Health? Syneos Health has a market capitalization of $4.40 billion and generates $4.39 billion in revenue each year. The company earns $24.28 million in net income (profit) each year or $2.62 on an earnings per share basis. Syneos Health employs 24,000 workers across the globe. What is Syneos Health's official website? The official website for Syneos Health is http://www.syneoshealth.com/. How can I contact Syneos Health? Syneos Health's mailing address is 1030 Sync Street, Morrisville NC, 27560. The company can be reached via phone at 919-876-9300 or via email at [email protected] MarketBeat Community Rating for Syneos Health (NASDAQ SYNH)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 441 (Vote Outperform)Underperform Votes: 359 (Vote Underperform)Total Votes: 800MarketBeat's community ratings are surveys of what our community members think about Syneos Health and other stocks. Vote "Outperform" if you believe SYNH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYNH will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/25/2019 by MarketBeat.com StaffFeatured Article: Percentage Gainers Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.